Filing Flows › Vera Therapeutics (VERA) › Q3 2026
Vera Therapeutics (VERA) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Vera Therapeutics (VERA) reported revenue of $10.3M for the third quarter 2026 (Q3 2026). Operating margin was -931.2%, net loss $93.7M (911.9% of revenue).
Vera Therapeutics, Q3 2026: revenue $10.3M, operating margin -931.2%, net loss $93.7M, operating cash flow −$99.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.3M | — | — |
| Operating profit | −$95.7M | — | — |
| Net earnings | −$93.7M | — | — |
| Operating cash flow | −$99.2M | — | — |
What changed
Revenue was $10.3M in Q3 2026.
Operating costs exceeded revenue by $95.7M, an operating margin of -931.2%. The quarter ended with a net loss of $93.7M.
Operating cash flow was −$99.2M. Non-cash charges added back $823K of depreciation and amortization and $15.7M of share-based compensation. Working capital and other items used $22.0M.
Questions
What was Vera Therapeutics' revenue in the third quarter 2026?
Vera Therapeutics (VERA) reported revenue of $10.3M for the third quarter 2026 (Q3 2026).
Was Vera Therapeutics profitable in the third quarter 2026?
Operating loss was $95.7M (-931.2% of revenue) and net loss $93.7M.
Source: Vera Therapeutics 10-Q on SEC EDGAR.